AMYT   $14.7  0.20% Market Closed

Amryt Pharma PLC
Total Cash
totalCashPerShare
EBITDA
Total Debt
quickRatio
currentRatio
Total Revenue
debtToEquity
Revenue/Share
ROA
ROE
grossProfits 120.84M
freeCashflow
operatingCashflow
earningsGrowth
revenueGrowth
grossMargins
ebitdaMargins
operatingMargins
profitMargins
enterpriseValue
forwardPE
floatShares
sharesOutstanding
sharesShort
sharesShortPriorMonth
dateShortInterest
sharesPercentSharesOut
heldPercentInsiders
heldPercentInstitutions
Short Ratio help_outline
shortPercentOfFloat
impliedSharesOutstanding
bookValue
Price To Book help_outline
earningsQuarterlyGrowth
netIncomeToCommon
trailingEps
forwardEps
enterpriseToEbitda
lastDividendValue
lastDividendDate
currentQuarterEstimate -0.03 4Q 2022
institutionsCount
lastUpdated Nov. 7, 2024, 3:18 a.m.